Inhibition of MARCKS activity by a PKC inhibitor enzastaurin or siRNA-mediated knockdown significantly enhanced the sensitivity of resistant myeloma cell lines and primary myeloma samples to therapy. This evidence concerns the gene MARCKS and plasma cell myeloma.